Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 14464-68-7
2. 3-(trifluoromethyl)-l-phenylalanine
3. 3-trifluoromethyl-l-phenylalanine
4. L-3-trifluoromethylphenylalanine
5. (2s)-2-amino-3-[3-(trifluoromethyl)phenyl]propanoic Acid
6. L-3-trifluoromethyphenylalanine
7. L-phenylalanine, 3-(trifluoromethyl)-
8. Mfcd00044945
9. (2s)-2-azanyl-3-[3-(trifluoromethyl)phenyl]propanoic Acid
10. D-3-trifluoromethyphenylalanine
11. L-3-trifluoromethylphe
12. Phenylalanine, 3-(trifluoromethyl)-
13. Schembl44156
14. (s)-2-amino-3-(3-(trifluoromethyl)phenyl)propanoicacid
15. Chembl4247645
16. Chebi:232678
17. Akos010366800
18. Akos015852790
19. Ac-5862
20. Js-4131
21. Cs-0312896
22. A50119
23. En300-199898
24. 3-(trifluoromethyl)-l-phenylalanine, >=96% (hplc)
25. D-phenylalanine,3-(trifluoromethyl)-,hydrochloride(9ci)
26. Fx9
| Molecular Weight | 233.19 g/mol |
|---|---|
| Molecular Formula | C10H10F3NO2 |
| XLogP3 | -0.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 63.3 |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 255 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
The two companies will collaborate to co-develop and co-commercialise ZP8396 (petrelintide) in combination with CT-388 for the treatment of obesity.
Lead Product(s): Petrelintide,CT-388
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Peptide, Unconjugated
Sponsor: F. Hoffmann-La Roche
Deal Size: $5,300.0 million Upfront Cash: $1,650.0 million
Deal Type: Collaboration March 12, 2025
Lead Product(s) : Petrelintide,CT-388
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : $5,300.0 million
Deal Type : Collaboration
Roche & Zealand Partner to Develop Petrelintide for Obesity & Overweight Therapy
Details : The two companies will collaborate to co-develop and co-commercialise ZP8396 (petrelintide) in combination with CT-388 for the treatment of obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : $1,650.0 million
March 12, 2025
Details:
CT-388 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.
Lead Product(s): CT-388,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: F. Hoffmann-La Roche
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 08, 2024
Lead Product(s) : CT-388,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
Details : CT-388 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 08, 2024
Details:
CT-388 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.
Lead Product(s): CT-388,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: F. Hoffmann-La Roche
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 29, 2024
Lead Product(s) : CT-388,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CT-388 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 29, 2024
Details:
CT-388 is a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist, which is being developed for the treatment of obesity and type 2 diabetes.
Lead Product(s): CT-388,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 16, 2024
Lead Product(s) : CT-388,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Roche Reports Positive Phase I Results For CT-388 In Obesity
Details : CT-388 is a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist, which is being developed for the treatment of obesity and type 2 diabetes.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 16, 2024
Details:
CT-388, a dual GLP-1/GIP receptor agonist, weekly subcutaneous injection is being evaluated in the Phase I clinical trial studies for the treatment of obesity and type 2 diabetes.
Lead Product(s): CT-388,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 16, 2024
Lead Product(s) : CT-388,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Genentech Reports Positive Phase Ib Results For CT-388 In Obesity
Details : CT-388, a dual GLP-1/GIP receptor agonist, weekly subcutaneous injection is being evaluated in the Phase I clinical trial studies for the treatment of obesity and type 2 diabetes.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 16, 2024
Details:
Roche will enhance its portfolio with Carmot’s GLP-1/GIP receptor agonists, including CT-388, CT-996, and CT-868, for metabolic diseases like obesity and diabetes.
Lead Product(s): CT-388,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: F. Hoffmann-La Roche
Deal Size: $3,100.0 million Upfront Cash: $2,700.0 million
Deal Type: Acquisition January 29, 2024
Lead Product(s) : CT-388,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : $3,100.0 million
Deal Type : Acquisition
Carmot Therapeutics Announces Completion of Acquisition by Roche
Details : Roche will enhance its portfolio with Carmot’s GLP-1/GIP receptor agonists, including CT-388, CT-996, and CT-868, for metabolic diseases like obesity and diabetes.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : $2,700.0 million
January 29, 2024
Details:
Through the acquisition, Roche will build its portfolio by adding Carmot’s pipeline of GLP-1/GIP receptor agonist, including CT-388, CT-996 and CT-868 which are being evaluated for the treatment of metabolic diseases including obesity and diabetes.
Lead Product(s): CT-388,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: F. Hoffmann-La Roche
Deal Size: $3,100.0 million Upfront Cash: $2,700.0 million
Deal Type: Acquisition December 04, 2023
Lead Product(s) : CT-388,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : $3,100.0 million
Deal Type : Acquisition
Carmot Therapeutics Enters into Definitive Merger Agreement with Roche
Details : Through the acquisition, Roche will build its portfolio by adding Carmot’s pipeline of GLP-1/GIP receptor agonist, including CT-388, CT-996 and CT-868 which are being evaluated for the treatment of metabolic diseases including obesity and diabetes.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : $2,700.0 million
December 04, 2023
Details:
The net proceeds will be used to advance the clinical development of CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, for the treatment of type-2 diabetes and obesity.
Lead Product(s): CT-388,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Peptide, Unconjugated
Sponsor: J.P. Morgan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering November 17, 2023
Lead Product(s) : CT-388,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : Undisclosed
Deal Type : Public Offering
Obesity and Diabetes Biotech Carmot Therapeutics Files for IPO
Details : The net proceeds will be used to advance the clinical development of CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, for the treatment of type-2 diabetes and obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
November 17, 2023
Details:
The proceeds will be used to strengthen Carmot's portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis, including CT-388, a dual GLP-1/GIP receptor modulator for obese adults with and without type 2 diabetes.
Lead Product(s): CT-388,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Deep Track Capital
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Series E Financing May 25, 2023
Lead Product(s) : CT-388,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Deep Track Capital
Deal Size : $150.0 million
Deal Type : Series E Financing
Details : The proceeds will be used to strengthen Carmot's portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis, including CT-388, a dual GLP-1/GIP receptor modulator for obese adults with and withou...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
May 25, 2023
Details:
The spin-off enables Carmot to focus on clinical-stage candidates CT-388 and CT-868 (dual GLP-1/GIP receptor modulators), additional IND-stage programs including CT-996 (an oral, small molecule GLP-1 receptor agonist) and a long-acting PYY analogue.
Lead Product(s): CT-388,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Carmot Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Demerger January 05, 2023
Lead Product(s) : CT-388,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Carmot Therapeutics
Deal Size : Undisclosed
Deal Type : Demerger
Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease
Details : The spin-off enables Carmot to focus on clinical-stage candidates CT-388 and CT-868 (dual GLP-1/GIP receptor modulators), additional IND-stage programs including CT-996 (an oral, small molecule GLP-1 receptor agonist) and a long-acting PYY analogue.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
January 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
87
PharmaCompass offers a list of CT-388 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right CT-388 manufacturer or CT-388 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred CT-388 manufacturer or CT-388 supplier.
PharmaCompass also assists you with knowing the CT-388 API Price utilized in the formulation of products. CT-388 API Price is not always fixed or binding as the CT-388 Price is obtained through a variety of data sources. The CT-388 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A CT-388 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CT-388, including repackagers and relabelers. The FDA regulates CT-388 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CT-388 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A CT-388 supplier is an individual or a company that provides CT-388 active pharmaceutical ingredient (API) or CT-388 finished formulations upon request. The CT-388 suppliers may include CT-388 API manufacturers, exporters, distributors and traders.
CT-388 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CT-388 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CT-388 GMP manufacturer or CT-388 GMP API supplier for your needs.
A CT-388 CoA (Certificate of Analysis) is a formal document that attests to CT-388's compliance with CT-388 specifications and serves as a tool for batch-level quality control.
CT-388 CoA mostly includes findings from lab analyses of a specific batch. For each CT-388 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CT-388 may be tested according to a variety of international standards, such as European Pharmacopoeia (CT-388 EP), CT-388 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CT-388 USP).
